RxDoctor Payments Data

Randall Bashore, MD

Internal Medicine · New Canton, VANPI 1992783286

Payments from drug & device makers

$314in general payments, 2019–2025

Across 18 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$122
  • AbbVie$48
  • Novo Nordisk$33
  • Bayer$28
  • Lilly USA, LLC$23
  • Alkermes, Inc.$19
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$314 in reported general payments places this provider in the 60th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$19,933
Medicare patients
201
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban462$195,794
JanuviaSitagliptin Phosphate168$71,472
TrulicityDulaglutide107$66,131
JardianceEmpagliflozin72$45,542
OzempicSemaglutide36$44,360
Tadalafil23$43,140
XareltoRivaroxaban52$36,390
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$33,301
Invega SustennaPaliperidone Palmitate13$23,423
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$19,730
Breo ElliptaFluticasone/Vilanterol45$18,355
FarxigaDapagliflozin Propanediol27$17,025
Incruse ElliptaUmeclidinium Bromide38$13,442
Humalog Kwikpen U-100Insulin Lispro47$9,858
Atorvastatin Calcium700$9,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$122$202,876486 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$12$84,829175 claims
Lilly USA, LLCTrulicity$23$66,131107 claims
Novo NordiskOzempic, Levemir$33$48,37852 claims
AbbVieNamzaric$48$4,69916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in New Canton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →